Supports Second Generic Semaglutide Approval in Canada - OneSource Specialty Pharma Ltd

Code BSE: 544292 NSE:

The second generic semaglutide approval in Canada, positioning OneSource partners as the first generic entrants in one of the world’s most significant semaglutide markets. The milestone reflects a closely integrated development and manufacturing model. Orbicular led the product development and technical program for the complex peptide, while OneSource supported the program as the manufacturing partner, providing end-to-end manufacturing capabilities for the Canadian filing. Commercial supply will be supported from OneSource’s US FDA-approved flagship facility in Bengaluru.